All In Biotech

Drug Trial Radar · NCT05221398

Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma

Adjuvant Immune CheckPoint InhibitoRs Based ThErapy in PostoperatiVe HEpatocellular CarciNoma: a ProspecTive Real-world Study

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Mar 3, 2019

Primary completion

Dec 18, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Guangxi Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 3, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • Immune Checkpoint Inhibitors Based Adjuvant therapyDrug

    Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy

  • Active surveillanceOther

    Patients in this group only receive active surveillance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survivialTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jian-Hong Zhong

    Nanning, Guangxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.